The two largest health insurers in Massachusetts are effectively telling the drug companies that they may seek a rapidly ...

Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this ...

GLP-1 drugs like Ozempic® and Zepbound® have gained significant attention for treating both diabetes and assisting with weight loss.

A current weight-loss and diabetes drug has become a surprise candidate for migraine treatment, with a new pilot study ...

The country’s Medicines and Healthcare products Regulatory Agency’s (MHRA) Yellow Card scheme, the UK’s official system for ...

Insurers are cutting coverage, citing costs. But there’s seldom any discussion of the return on investment from these drugs ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Market quiet, Nifty futures subdued, Asian markets lower. Analysts predict benefits for Indian contract manufacturers from ...

Discover why Novo Nordisk's current sell-off offers a strong buy opportunity. Backed by solid fundamentals, growth prospects, ...

When looking for a high-protein snack that supports gut health, there are some snacks that check both of those boxes. When we ...

These ASX 200 healthcare shares, including Mesoblast Ltd (ASX: MSB) and Resmed Inc CDI (ASX: RMD), were in great health in ...